Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation

NCT04698850 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

OTHER_GOV

Sponsor class

Stopped funding issues

Conditions

Wet Macular Degeneration

Interventions

DRUG: Aflibercept 40 MG/ML [Eylea]
DRUG: Brolucizumab-Dbll 120 MG/ML [Beovu]
DRUG: Ranibizumab 6 MG/ML [Lucentis]

Sponsor

Faculty Hospital Kralovske Vinohrady